相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Single-Dose, Placebo-Controlled, Randomized Study of AMG 785, a Sclerostin Monoclonal Antibody
Desmond Padhi et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2011)
First Missense Mutation in the SOST Gene Causing Sclerosteosis by Loss of Sclerostin Function
Elke Piters et al.
HUMAN MUTATION (2010)
Fra-2/AP-1 controls bone formation by regulating osteoblast differentiation and collagen production
Aline Bozec et al.
JOURNAL OF CELL BIOLOGY (2010)
Increased Sclerostin Serum Levels Associated with Bone Formation and Resorption Markers in Patients with Immobilization-Induced Bone Loss
Agostino Gaudio et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2010)
Altered Skeletal Expression of Sclerostin and Its Link to Radiographic Progression in Ankylosing Spondylitis
Heiner Appel et al.
ARTHRITIS AND RHEUMATISM (2009)
Sclerostin Antibody Treatment Increases Bone Formation, Bone Mass, and Bone Strength in a Rat Model of Postmenopausal Osteoporosis
Xiaodong Li et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2009)
Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma
R. A. Kyle et al.
LEUKEMIA (2009)
Soluble decoy receptor 3 modulates the survival and formation of osteoclasts from multiple myeloma bone disease patients
S. Colucci et al.
LEUKEMIA (2009)
Production of Wnt inhibitors by myeloma cells: Potential effects on canonical Wnt pathway in the bone microenvironment
Nicola Giuliani et al.
CANCER RESEARCH (2007)
Regulation of bone mass by Wnt signaling
V Krishnan et al.
JOURNAL OF CLINICAL INVESTIGATION (2006)
Wnt signalling in osteoblasts regulates expression of the receptor activator of NFκB ligand and inhibits osteoclastogenesis in vitro
GJ Spencer et al.
JOURNAL OF CELL SCIENCE (2006)
Myeloma cells suppress bone formation by secreting a soluble Wnt inhibitor, sFRP-2
T Oshima et al.
BLOOD (2005)
Myeloma cells block RUNX2/CBFA1 activity in human bone marrow osteoblast progenitors and inhibit osteoblast formation and differentiation
N Giuliani et al.
BLOOD (2005)
SOST/sclerostin, an osteocyte-derived negative regulator of bone formation
RL Bezooijen et al.
CYTOKINE & GROWTH FACTOR REVIEWS (2005)
L-carnitine and isovaleryl L-carnitine fumarate positively affect human osteoblast proliferation and differentiation in vitro
S Colucci et al.
CALCIFIED TISSUE INTERNATIONAL (2005)
International staging system for multiple myeloma
PR Greipp et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Sclerostin is an osteocyte-expressed negative regulator of bone formation, but not a classical BMP antagonist
RL van Bezooijen et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2004)
The Fos-related antigen Fra-1 is an activator of bone matrix formation
R Eferl et al.
EMBO JOURNAL (2004)
T cells support osteoclastogenesis in an in vitro model derived from human multiple myeloma bone disease: the role of the OPG/TRAIL interaction
S Colucci et al.
BLOOD (2004)
The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma
E Tian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
AP-1: A double-edged sword in tumorigenesis
R Eferl et al.
NATURE REVIEWS CANCER (2003)
Osteoclast differentiation and activation
WJ Boyle et al.
NATURE (2003)
A 52-kb deletion in the SOST-MEOX1 intergenic region on 17q12-q21 is associated with van Buchem disease in the Dutch population
K Staehling-Hampton et al.
AMERICAN JOURNAL OF MEDICAL GENETICS (2002)
Identification of a 52 kb deletion downstream of the SOST gene in patients with van Buchem disease
W Balemans et al.
JOURNAL OF MEDICAL GENETICS (2002)
LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development
YQ Gong et al.
CELL (2001)
Cbfa1 contributes to the osteoblast-specific expression of type I collagen genes
B Kern et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST)
W Balemans et al.
HUMAN MOLECULAR GENETICS (2001)
分享论文
